Impact of immunosuppressive drugs on circulating Tfh cells in kidney transplant recipients: A pilot study

Transpl Immunol. 2018 Feb:46:1-7. doi: 10.1016/j.trim.2017.09.005. Epub 2017 Sep 30.

Abstract

Background: T follicular helper cells (Tfh) are recently revealed to be vital in antibody-mediated rejection (AMR) in kidney transplant recipients (KTRs). However, the impact of immunosuppressive drugs on Tfh cells is not fully understood. The purpose of this study was to investigate the variation of Tfh cells phenotypically and functionally in KTRs treated with different immunosuppression regimens.

Methods: We recruited 26 KTRs treated with tacrolimus (TAC) -based regimen, 13 with sirolimus (SRL) -based regimen and 10 healthy controls (HC) in this study. The percentage and absolute number of circulating Tfh cells and the co-expression of Tfh related molecules including inducible costimulatory molecule (ICOS), programmed cell death protein 1 (PD-1), interleukin-21 (IL-21) and signal transducer and activator of transcription 3 (STAT3) were analyzed by flow cytometry, while serum IL-6 was detected by electrochemiluminescence immunoassay.

Results: The percentage and absolute number of Tfh cells and the co-expression of PD-1, STAT3 in Tfh cells were significantly higher in TAC group than that in SRL group. While no difference was found in regard to IL-21 and ICOS co-expressed with Tfh cells among three groups. Multiple linear regression analysis results showed that pre-transplant PRA level was the significant confounder affecting the absolute numbers of Tfh and CD4+CXCR5+PD-1+ T cells. In addition, correlation analysis showed that CD4+CXCR5+STAT3+ T cells were positively correlated to Tfh cells.

Conclusions: Our study indicates that sirolimus can suppress the quantity of Tfh cells more significantly than tacrolimus. The higher level of circulating Tfh cells in tacrolimus group might be related to STAT3 signaling.

Keywords: Kidney transplantation; Signal transducer and activator of transcription 3; Sirolimus; T follicular helper cells; Tacrolimus.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibody-Dependent Cell Cytotoxicity
  • Female
  • Germinal Center / immunology*
  • Graft Rejection / immunology*
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Inducible T-Cell Co-Stimulator Protein / metabolism
  • Isoantibodies / metabolism
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Pilot Projects
  • Programmed Cell Death 1 Receptor / metabolism
  • Receptors, CXCR5 / metabolism
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction
  • Sirolimus / therapeutic use*
  • T-Lymphocytes, Helper-Inducer / immunology*
  • Tacrolimus / therapeutic use*

Substances

  • CXCR5 protein, human
  • Immunosuppressive Agents
  • Inducible T-Cell Co-Stimulator Protein
  • Isoantibodies
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, CXCR5
  • STAT3 Transcription Factor
  • Sirolimus
  • Tacrolimus